Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.
To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD’s next generation Instinct™ MI355X GPUs.
“Our mission is to push the boundaries of how we design new therapeutics,” said Sean McClain, Founder and CEO, Absci. “With OCI and AMD, we are pairing our cutting-edge AI models with best‑in‑class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows.”
https://finance.yahoo.com/news/absci-accelerates-ai-driven-drug-120000640.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.